At the San Antonio Breast Cancer Symposium, Jennifer Specht, MD, of the University of Washington and Fred Hutch Cancer Center, Seattle, presented results from the ECOG-ACRIN FEATURE trial, a phase II ...
Staging locally advanced breast cancer patients with 18 F-labeled fluorodeoxyglucose (FDG) PET-CT detected more distant metastases -- and thus reduced the number of patients who received combined ...
Background Cardiac sarcoidosis (CS) creates complex treatment challenges, especially for patients who fail to respond to ...
Efficacy and safety of camrelizumab combined with chemotherapy (irinotecan combined with platinum) followed by camrelizumab combined with apatinib in the first-line treatment of advanced small cell ...
For patients with head and neck squamous cell carcinoma, utilizing fluorodeoxyglucose-(FDG)-PET/CT imaging to assess their response to chemoradiation significantly increases the accuracy in ...
Expert Rev Anticancer Ther. 2009;9(1):75-96. Based on the available data, FDG-PET alone appears to be of limited use in differentiating tumors of low malignant potential from benign tumors and ovarian ...
Visual Abstract. Comparison of FDG PET 3D-SSP z score maps and transaxial slices of the temporal lobe, along with corresponding MRI images, among individuals suspected of having Alzheimer's disease ...
Positron emission tomography (PET) scans can detect cancer earlier than other imaging tests. But some types of cancer are harder to detect on a PET scan. In particular, they may miss cancers that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results